Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALOGLIPTIN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus,Combination therapy with metformin, sulfonylurea, thiazolidinedione, or insulin
Mild to moderate pain,Fever
25 mg orally once daily
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is approximately 12-21 hours. This supports once-daily dosing. In patients with renal impairment, half-life is prolonged (e.g., up to 32 hours in severe impairment), necessitating dose adjustment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Alogliptin is minimally metabolized; approximately 60-70% excreted unchanged in urine. Metabolism involves hepatic microsomal enzymes, primarily CYP2D6 and CYP3A4, but to a minor extent.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Approximately 60-71% of the dose is excreted unchanged in urine via active renal tubular secretion, with about 20% eliminated as metabolites (primarily N-demethylated and N-acetylated derivatives) in urine, and less than 2% in feces. Renal excretion is the major route.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
20% bound to plasma proteins, primarily albumin. Binding is concentration-independent.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution is approximately 33 L (0.47 L/kg assuming 70 kg). This suggests distribution into total body water, but not extensive tissue binding.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability is approximately 100%, indicating complete absorption with minimal first-pass metabolism.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
e GFR 30-59 m L/min: 12.5 mg orally once daily; e GFR 15-29 m L/min: 6.25 mg orally once daily; e GFR <15 m L/min or dialysis: 6.25 mg orally once daily
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A and B); not recommended for severe hepatic impairment (Child-Pugh C)
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Safety and efficacy not established; no recommended dosing available
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No dose adjustment recommended based on age alone; monitor renal function and adjust dose accordingly
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Pancreatitis: Cases of acute pancreatitis have been reported; discontinue if pancreatitis is suspected.,Hypersensitivity reactions: Including anaphylaxis, angioedema, and severe cutaneous adverse reactions.,Heart failure: Consider risk factors; monitor for signs and symptoms.,Severe and disabling arthralgia has been reported.,Acute renal failure: Not recommended in patients with severe renal impairment (e GFR < 30 m L/min/1.73 m²) or end-stage renal disease.,Hypoglycemia when used in combination with insulin or sulfonylureas.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
History of serious hypersensitivity reaction to alogliptin or any excipient,Type 1 diabetes mellitus,Diabetic ketoacidosis
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions; can be taken with or without food. Avoid excessive alcohol intake due to potential hypoglycemia risk when used with other agents.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and well-controlled studies in pregnant women exist. Use only if clearly needed. First trimester risk cannot be ruled out; limited human data.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
It is unknown if alogliptin is excreted in human breast milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account importance to the mother.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No specific dose adjustments recommended; however, pregnancy may alter pharmacokinetics of alogliptin. Avoid use when possible, particularly during the second and third trimesters, due to limited safety data.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Alogliptin is a DPP-4 inhibitor with minimal risk of hypoglycemia when used as monotherapy; dosing adjustments required for renal impairment (creatinine clearance <60 m L/min). Monitor for acute pancreatitis and severe arthralgia. No significant weight loss or gain. Use with caution in patients with history of pancreatitis.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take alogliptin with or without food once daily.,Do not skip meals, especially if taking other diabetes medications that cause hypoglycemia.,Contact healthcare provider immediately if you experience persistent severe abdominal pain (sign of pancreatitis).,Report any joint pain that is new or worsening.,Store at room temperature away from moisture and heat.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Sunitinib, a tyrosine kinase inhibitor, may enhance the glucose-lowering effects of alogliptin, a DPP-4 inhibitor, by impairing renal function and potentially reducing the renal clearance of alogliptin, leading to increased exposure and risk of hypoglycemia. This interaction is particularly relevant in patients with pre-existing renal impairment or those receiving high-dose sunitinib. Clinical outcomes include episodes of symptomatic hypoglycemia, which may require dose adjustment of antidiabetic therapy."
"Alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, enhancing glucose-dependent insulin secretion. Mesalazine, known for its anti-inflammatory effects in inflammatory bowel disease, may independently lower blood glucose via unknown mechanisms. Concurrent use could potentiate hypoglycemic effects, especially in patients with diabetes or impaired glucose regulation, increasing the risk of symptomatic hypoglycemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALOGLIPTIN vs ACEPHEN, answered by our medical review team.
ALOGLIPTIN is a DPP-4 Inhibitor that works by Alogliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4). By inhibiting DPP-4, it increases the levels of active incretin hormones (GLP-1 and GIP), which stimulate insulin secretion in a glucose-dependent manner and suppress glucagon release, thereby improving glycemic control.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALOGLIPTIN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALOGLIPTIN is: 25 mg orally once daily. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALOGLIPTIN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALOGLIPTIN is classified as Category C. Alogliptin is classified as FDA Pregnancy Category B. Animal studies showed no teratogenic effects at exposures up to 100 times the human clinical dose. However, no adequate and we. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.